MRC Clinical Trials Unit at UCL
90 High Holborn
London
WC1V 6LJ
ICON8 and ICON8B: mrcctu.icon8and8b@ucl.ac.uk
ICON8B Trial Schema and aims
|
Stage 1 |
Safety of Bevacizumab in combination with DPS |
|---|---|
|
Stage 2 |
Primary outcome measure: Progression-free Survival and Overall Survival. Secondary outcome measure: Toxicity, Quality of Life and Health Economics |
|
Ancillary studies: |
Translational Research, Health Economics, QoL Study |
ICON8 and ICON8B